Long QT Syndrome
Pipeline by Development Stage
Competitive Landscape
12 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (15)
Total enrollment: 5,728 patients across 15 trials
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Long QT Syndrome Screening in Newborns
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Phase 1 Study of LQT-1213 in Healthy Adults
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Study of the Effect of GS-6615 in Subjects With LQT-3
KCNQ1 Cascade Screening
Prospective Identification of Long QT Syndrome in Fetal Life
Genetics of QT Prolongation With Antiarrhythmics
Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.